Sclerostin antibody + DKK1 antibody

Sclerostin antibody + DKK1 antibody decreases cortical porosity in mice.

“Cortical porosity in aged mice was also reduced by both Scl-mAb and low-dose 3:1 treatment.”

Animals

Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton

Aging and disease·Dec 1, 2022

Sclerostin antibody + DKK1 antibody improves bone mineral density in mice.

“For some bone properties, including trabecular thickness and bone mineral density in the spine, and endocortical bone formation rates in the femur, the 3:1 treatment was associated with significantly improved skeletal properties”

Animalscompared to twice the dose of Scl-mAbspine12.5 mg/kg

Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton

Aging and disease·Dec 1, 2022

Sclerostin antibody + DKK1 antibody improves bone mass in mice (12.5 mg/kg vs 25 mg/kg).

“A 3:1 dose of Scl-mAb:Dkk1-mAb at 12.5 mg/kg was equally efficacious as 25 mg/kg of Scl-mAb in both age groups”

Animals12.5 mg/kg

Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton

Aging and disease·Dec 1, 2022